Genprex

Update in progress

GNPX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Genprex is a clinical-stage gene therapy company focused on cancer and diabetes. Its oncology program uses the systemic, non-viral Oncoprex Delivery System to deliver gene-instructed therapies via lipid nanoparticles. Lead candidate Reqorsa Gene Therapy (quaratusugene ozeplasmid) targets NSCLC, SCLC, and mesothelioma, with FDA designations for three lung cancers and orphan status for SCLC. Its diabetes program uses AAV-delivered Pdx1 and MafA (GPX-002) to restore insulin production. Based in Austin, TX, since 2009, it collaborates with MD Anderson, UM Rogel Cancer Center, and others.

Company score

Sentiment: 0.30; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.13; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.01; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive